Why We Do It

The biomedical enterprise is one of the supreme achievements of humankind. Surely, creating a useful therapeutic or vaccine compares with the feat of sending a man to the moon (except that a moonshot is less expensive). Biosyntax seeks to play a supportive role in this enterprise and convey the accomplishments of those who take it forward.

The company was founded by Richard Koenig, who brings to the service of Biosyntax clients his communications experience of three decades. He has held global responsibilities for corporate, product, R&D, and employee communications at one of the world's largest pharmaceutical companies (GlaxoSmithKline plc), headed media and investor relations at one of the world's most productive biotechnology companies (Centocor, Inc., before its acquisition by Johnson & Johnson), and written hundreds of articles for the world's leading business publication (The Wall Street Journal).